Citigroup Cuts LENZ Therapeutics (NASDAQ:LENZ) Price Target to $26.00

LENZ Therapeutics (NASDAQ:LENZ) had its price objective cut by Citigroup from $52.00 to $26.00 in a research report released on Thursday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other research analysts also recently weighed in on the stock. Bank of America lowered their price objective on shares of LENZ Therapeutics from $35.00 to $29.00 and set a “buy” rating on the stock in a report on Wednesday. Wall Street Zen downgraded shares of LENZ Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. HC Wainwright reissued a “buy” rating on shares of LENZ Therapeutics in a research report on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of LENZ Therapeutics in a report on Thursday, January 22nd. Finally, William Blair reaffirmed an “outperform” rating on shares of LENZ Therapeutics in a research report on Tuesday, March 10th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, LENZ Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

LENZ Therapeutics Stock Down 6.0%

Shares of LENZ opened at $8.40 on Thursday. LENZ Therapeutics has a 12-month low of $8.40 and a 12-month high of $50.40. The stock has a market cap of $263.34 million, a PE ratio of -2.99 and a beta of 0.52. The business has a 50-day simple moving average of $13.75 and a two-hundred day simple moving average of $23.97.

LENZ Therapeutics (NASDAQ:LENZ) last announced its earnings results on Tuesday, March 24th. The company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.91) by ($0.25). The company had revenue of $1.59 million for the quarter, compared to analyst estimates of $3.09 million. On average, equities research analysts expect that LENZ Therapeutics will post -2.18 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Rockefeller Capital Management L.P. increased its stake in LENZ Therapeutics by 167.1% in the fourth quarter. Rockefeller Capital Management L.P. now owns 48,071 shares of the company’s stock valued at $769,000 after acquiring an additional 30,071 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in LENZ Therapeutics in the fourth quarter valued at approximately $59,000. Aristides Capital LLC purchased a new position in shares of LENZ Therapeutics in the fourth quarter worth $168,000. Virtu Financial LLC bought a new stake in shares of LENZ Therapeutics in the fourth quarter worth about $198,000. Finally, XTX Topco Ltd bought a new stake in shares of LENZ Therapeutics in the 4th quarter worth approximately $1,373,000. 54.32% of the stock is currently owned by institutional investors.

LENZ Therapeutics News Roundup

Here are the key news stories impacting LENZ Therapeutics this week:

• Positive Sentiment: HC Wainwright raised near-term EPS forecasts for Q1 and Q2 2026 and upgraded FY2026/2027 trajectory (estimates moved closer to break-even), signaling improving visibility on operating performance. (Source: HC Wainwright research note)
• Positive Sentiment: HC Wainwright published a long‑term bullish projection (FY2030 EPS of $3.18), reflecting confidence in LENZ’s longer‑term commercialization or pipeline upside. (Source: HC Wainwright research note)
• Positive Sentiment: Bank of America set a new $29 price target for LENZ, which implies meaningful upside from current levels and may support buy-side interest. LENZ Therapeutics (NASDAQ:LENZ) Given New $29.00 Price Target at Bank of America
• Neutral Sentiment: Recent earnings call materials and coverage are available for review — useful for investors digging into guidance, R&D progress and management comments. Q4 2025 Earnings Call Summary Q4 2025 Earnings Call Transcript Analysts Offer Insights on Healthcare Companies
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate (from -$0.41 to -$0.48) and reduced several multi‑year forecasts (FY2028 and FY2029 down), which increases near‑term earnings uncertainty. (Source: HC Wainwright research notes)
• Negative Sentiment: LENZ reported a Q4 2025 earnings miss (EPS and revenue below consensus), a direct catalyst that likely pressured the stock and prompted analyst revisions. Q4 2025 Earnings Call Summary
• Negative Sentiment: Citigroup cut its price target sharply (from $52 to $26) despite keeping a buy rating — the lower PT reduces near‑term upside expectations from some institutional investors. Citigroup Lowers LENZ Price Target

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.